Biocon has announced the launch of its GLP-1 peptide Liraglutide for diabetes and obesity in the United Kingdom (U.K.).

Shares of Biocon Ltd took a hit on Friday, February 28, 2025, slipping to a day’s low of Rs 300.10, marking a 3.92 per cent ...

For both induction and maintenance therapy, subcutaneous guselkumab significantly improves clinical outcomes in patients with ...

Liraglutide in United Kingdom: Our Bureau, Bengaluru Friday, February 28, 2025, 15:30 Hrs [IST] Biocon Limited, an innovation-led global ...

Biocon Biologics India Limited is an Indian Non-Government Company. It's a public company and is classified as'company limited by shares'. Company's authorized capital stands at Rs 5.0 lakhs and has ...

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world ...